Scientific Publications Database

Article Title: Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER.
Authors: Baselga, Jose; Dent, Susan Faye; Cortes, Javier; Im, Young-Hyuck; Dieras, Veronique; Harbeck, Nadia; Krop, Ian E.; Verma, Sunil; Wilson, Timothy R.; Jin, Huan; Wang, Lijia; Schimmoller, Frauke; Hsu, Jerry Y.; He, Jing; DeLaurentiis, Michelino; Drullinsky, Pamela; Jacot, William
Journal: JOURNAL OF CLINICAL ONCOLOGY Volume 36 Issue 18
Date of Publication:2018
Abstract:
.